78597
document
The role of the MA-sensitive leukocyte chemotaxis in rheumatoid arthritis . A randomized double-blind clinical trial of griseofulvin treatment . Polymorphonuclear leukocyte ( PMN ) chemotaxis is thought to play an essential role in the pathogenesis of rheumatoid arthritis . PMN chemotaxis is in part sensitive to microtubule antagonists ( MAs ) , e.g . colchicine . The antimycotic antibiotic griseofulvin inhibits the MA-sensitive PMN chemotaxis in vitro in concentrations far below those obtained in serum during antimycotic therapy . The role of the MA-sensitive chemotaxis in rheumatoid arthritis could thus be elucidated by a clinical trial of griseofulvin treatment . Griseofulvin ( n = 20 ) was tested in a randomized double-blind study versus placebo ( m = 19 ) during one year in patients with rheumatoid arthritis of mild-moderate activity . No beneficial effect of griseofulvin treatment was noted on clinical symptoms or laboratory parameters of rheumatoid arthritis . Moreover , the placebo-treated patients showed more improvement than the griseofulvin-treated patients . It is therefore suggested that the MA-sensitive chemotaxis plays a reparative role in the inflammatory lesions of rheumatoid arthritis .
78598
Intervention_Pharmacological
griseofulvin
78599
Intervention_Pharmacological
griseofulvin
78600
Intervention_Physical
antimycotic therapy
78601
Intervention_Pharmacological
.
78602
Intervention_Physical
griseofulvin
78603
Intervention_Pharmacological
Griseofulvin
78604
Intervention_Control
placebo
78605
Intervention_Pharmacological
griseofulvin
78606
Intervention_Control
placebo-treated
78607
Intervention_Pharmacological
griseofulvin-treated
78608
Outcome_Other
beneficial effect
78609
Outcome_Other
improvement
78610
Participant_Condition
rheumatoid arthritis
78611
Participant_Sample-size
20
78612
Participant_Sample-size
19
78613
Participant_Condition
rheumatoid arthritis
78614
Participant_Condition
mild-moderate activity